Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Moderna leans on RSV vaccine, AI and a diversified pipeline to regain competitive edge

By Brian Buntz | August 3, 2023

Moderna logoModerna surged to prominence thanks to its rapid development of a competitive COVID-19 vaccine. Since the early days of the pandemic, however, the company has struggled to maintain its momentum. Year-to-date, its stock is down close to 40%, trading around $110 per share.

Adapting to COVID-19 variants

The company hopes that its development of vaccines for the XBB.1.5 COVID-19 variant will help bolster financial performance. “We are now awaiting approval to start for our updated COVID-19 vaccine applications to regulators globally,” Moderna CEO Stéphane Bancel said.

Developing a robust pipeline

Moderna CEO Stéphane Bancel has stressed in the past that Moderna is more than a COVID-19 company. “Our commercial team is also preparing for the 2024 launch of our next respiratory commercial product,” Bancel said. This product in question, a vaccine for respiratory syncytial virus (RSV) could potentially compete against products from GSK and Pfizer, among others.

In all, Moderna has 47 programs in its pipeline. This includes six programs in phase 3 and seven in phase 2. Outside of COVID-19 and RSV, the pipeline has candidates for flu, CMV, Zika and cancer.

Moderna places AI-driven strategy front and center

Another way Moderna aims to bolster its competitive edge is by integrating artificial intelligence (AI) across its operations. In 2021, it launched AI Academy, a mandatory corporate-level training initiative for its employees. “As of 2023, AI training is required for all Moderna team members, and we facilitate this training at the corporate level through our AI academy,” said Bancel in an earnings call.
“AI has been part of the foundation of Moderna’s research and development programs for several years,” Bancel said. “We have built our own AI models for protein and mRNA engineering, asset data analysis, regulatory interactions and many more use cases as we continue to be an AI leader in biopharma.”

The Boston Consulting Group honored Moderna as one of the world’s most innovative companies in part for its work in AI.

“I’m happy to share our AI implementation is accelerating for Moderna,” Bancel noted, adding that the use of the company’s large language model, mChat, has grown rapidly among employees since its introduction. “Around 50% of our employees use it already only 60 days after launch.”

The company is also working with IBM to explore drug discovery implications of quantum computing.

Acknowledging challenges

Despite its forward-looking strategies, Moderna has encountered some significant hurdles of late. The company incurred a $464 million write-off for expired vaccines and a $135 million charge from unused manufacturing capacity. This financial hit came about as a result of a significant shift to the company’s newly developed XBB.1.5 vaccine, which rendered its inventory of their previous bivalent omicron vaccine obsolete.

“In Q2, we reported revenues of approximately $300 million, reflecting the seasonal nature of endemic respiratory vaccines,” Bancel said. “This off-season quarter sales resulted in a GAAP net loss of $1.4 billion, GAAP diluted loss per share of $3.62.”
As the world gradually recovers from the pandemic, Moderna, and its contemporaries Pfizer and Novavax, is also seeing declining sales of COVID vaccines and therapeutics.

Moderna reported a net loss of $395 million and a 34% revenue decline to $5 billion in the fourth quarter, but raised its full-year 2023 outlook for its COVID-19 vaccine sales. The company now expects COVID-19 vaccine sales of $5 billion to $7 billion this year, down from $13.5 billion in 2022 but higher than previous estimates. This is driven by potential U.S. demand for 50-100 million doses in the fall. Moderna is banking on uptake of its updated Omicron-targeting bivalent booster shots to drive future COVID-19 vaccine sales and reverse the recent sales slump. Moderna, along with Pfizer and Novavax, have seen steep declines in COVID-19 vaccine sales as global demand weakens.

Strategic capital allocation and future plans

In the second quarter of 2023, Moderna repurchased 4.4 million shares for $600 million. Additionally, the company has invested in OriCiro (now Moderna Enzymatics), CytomX, Life Edit and Generation Bio in 2023, diversifying its investments and reinforcing its growth strategy.

Moderna’s global workforce of approximately 5,150 employees and its 17 commercial subsidiaries across North America, Europe and Asia Pacific are working to develop new revenue opportunities. The potential launch of an RSV product, among others, could position Moderna well for growth in 2024.

“Moderna has a promising commercial outlook,” Bancel noted.

 


Filed Under: Infectious Disease, machine learning and AI
Tagged With: AI in biopharma, biotech investments, COVID-19 vaccine, Moderna, pharma industry trends, RSV vaccine, vaccine development
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Secretary of Health removes all current members of the CDC advisory committee on immunization practices
covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE